Burrill believes the financial crisis has triggered changes in healthcare that have biotech executives “writing their new ‘play book’ in response.”
Here are some of Burrill’s thoughts on 2011 as published by Med City News:
Biotech and the capital markets: Expect to see the biotech industry continue to outperform the general markets as the financing environment continues to improve in 2011.
Biotech IPOs: Expect at least 25 biotech IPOs, possibly more, in the United States.
Capital: Financing – now at about $15 billion annually – and its market cap – at about $360 billion – will remain the same.
Partnering: Biotech-pharma partnerships will embrace “shared risk” and biotech can forget about the days of large upfront payments from pharma companies. Collaborations with China, India and Latin America will also increase.
Mergers & Acquisitions: Big pharma will finally start to gobble up biotechs. In particular, “Sanofi will finally seal the deal and acquire Genzyme and this will usher in several other marquee acquisitions of blue chip biotech companies.”
Pharma Restructuring: Job cuts and restructuring will continue.
Healthcare reform: The federal government, through Medicare and Medicaid, will create new regulatory and compensatory rules and, as a result, challenges for healthcare providers. Also, government will create “new regulations governing the development of biosimilars.”
Patent battles: The legal battle over the patentability of genes will heat up; uncertainty will continue to swirl around stem cells but regenerative medicine will be hot.
Clean tech will boom: The market will not only embrace green – from solar power to wind power to the next generation biofuels – but also technologies that improve energy efficiency and a clean environmental.
The Burrill Report is written for everyone who wants to understand how biotechnology operates as a business. Each month the publication focuses on the health of the industry and the strategies that will be needed to be successful. It provides actionable market intelligence on the latest global developments and trends in the life sciences industry.
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites